A

The Breast Tumor Microenvironment: Triple-Negative and HER2+ Carcinomas Have the Highest TIL and Are Most Likely to Be PD-L1

By Ashley Mathews 4 Videos
December 9, 2019
Copyright, College of American Pathologists, 2019. Used with permission.
0 Comments
Login to view comments. Click here to Login

Featured Video

17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Related Content

AUTOPLAY
27:39
Breast Health Global Initiative

Metastatic Breast Disease: Treatment and Palliative Care

Feat. A. Eniu
16:44
Heather McArthur

Modern Immune Therapy Strategies for Triple-Negative Breast Cancer

17:54
Heather McArthur

Modern Immune Therapy in ER, HR+/HER2-, HER2+ Breast Cancer

24:03
Holy Cross 9th Annual Winter Oncology Symposium

Early Stage Breast Cancer - Comparison of Trials of Genomic Assays -…

Feat. R. L. Mahtani
07:43
Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Feat. S. Goel
24:33
Holy Cross 9th Annual Winter Oncology Symposium

Therapeutic Strategies in HER2+ Breast Cancer - Pertuzumab, Neratini…

Feat. B. Moy
12:05
Holy Cross 9th Annual Winter Oncology Symposium

Future Directions in the Targeting of HER2+ Breast Cancer: duration …

Feat. B. Moy
10:12
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…

Feat. M. Abu-Khalaf
07:58
Sandra Swain

ASCO 2019 End-of-study Survival Analysis from the Cleopatra Study Sh…

10:53
Baltic and Eurasia Masterclass in Clinical Oncology

Neoadjuvant Systemic Therapy for HER2 + Early Breast Cancer - Review…

Feat. A. Česas
19:04
Baltic and Eurasia Masterclass in Clinical Oncology

Adjuvant Systemic Therapy for HER2 + Early Breast Cancer - Neratinib…

Feat. A. Česas
10:00
12th ESO-EONS Masterclass in Oncology Nursing

Breast Cancer Global Epidemiology (Nurses)

Feat. O. Pagani
07:58
12th ESO-EONS Masterclass in Oncology Nursing

Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Diseas…

Feat. O. Pagani
13:36
Baltic and Eurasia Masterclass in Clinical Oncology

Systemic Treatment of TNBC: Staging, BRCAness, Chemotherapy Prognost…

Feat. E. Kharchenko
19:29
2019 Scripps MD Anderson's Oncology Update

ASCO Metastatic HER2+ Breast Review: How Long to Treat Is up To Deba…

Feat. J. Mortimer
15:37
2019 MASCC/ISOO Annual Meeting on Supportive Care in Cancer

47 y/o Female with HER2+ Breast Cancer: Management of Chemotherapy-I…

Feat. M. Aapro, R. Clark-Snow, P. Fernandez-Ortega, E. Roeland
12:02
ANCO’s ASCO Highlights 2019

ANCO's ASCO Update on Breast Cancer - Margetuximab + Chemo Impr…

Feat. H. Chew
10:06
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherap…

Feat. J. Abraham, W. Gradishar
18:20
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Review of HER2 Testing Guidelines in Breast Cancer With Cases - IHC …

Feat. D. Hicks
08:27
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Therapeutic Options for Systemic Treatment of TNBC & New Data on…

Feat. D. Hicks